Drugs / Milataxel
Milataxel
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00685204 | Mar 2008 → ? | mesothelioma | Taxolog Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00063219 | ? → Feb 2005 | non-small cell lung carcinoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00063427 | ? → Feb 2004 | colonic neoplasm, rectal neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Milataxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00685204 ↗ |
| Known as | MAC-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00063219 ↗ |
| Known as | TL139 | “An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma” NCT00685204 ↗ |
| Modality | Small molecule | “Milataxel is a new taxane” NCT00685204 ↗ |
| Route | Intravenous | “MAC-321 intravenously every 3 weeks” NCT00063219 ↗ |